Federal update: DOJ partially rescheduled medical cannabis to Schedule III (April 28, 2026 final order). State-licensed medical operators may apply for expedited DEA registration through June 27, 2026; DEA hearing on full rescheduling set for June 29, 2026.

Stimulating

"Stimulating" cannabis effects encompass alertness, talkativeness, sociability, energy, and creative fluency. Low-to-moderate THC doses can produce dopaminergic disinhibition in prefrontal and striatal circuits, briefly mimicking features of mild psychostimulant action before giving way to sedation at higher doses or later in the time course. THCV, at low doses, acts as a CB1 neutral antagonist and has been reported to blunt THC's appetite- and sedation-promoting effects (Englund et al. 2016 J Psychopharmacol), providing a plausible mechanism for "stimulating" high-THCV chemovars. Terpenes α-pinene and limonene have preclinical alerting/antidepressant data (Russo 2011). Stimulating subjective profiles are anecdotally associated with "sativa-type" marketing, but chemovar labels do not reliably predict chemistry (Smith et al. 2022). ⚠️ Dose- and individual-dependent; reverses at higher doses. Citations: Englund A et al. J Psychopharmacol. 2016;30:140-151; Russo EB. Br J Pharmacol. 2011;163:1344-1364; Smith CJ et al. PLoS One. 2022;17(5):e0267498.